Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 13, 2020updated 25 Aug 2020 4:24pm

New Series B financing enables Reify Health to integrate trials

Cloud-based solutions provider Reify Health has raised $30m through Series B financing to advance its tools for the clinical trial ecosystem.

Cloud-based solutions provider Reify Health has raised $30m through Series B financing to advance its tools for the clinical trial ecosystem.

Led by Battery Ventures, the financing round also included participation from existing investors Sierra Ventures and Asset Management Ventures.

US-based Reify developed its platform ‘StudyTeam’ to upgrade the systems that health care personnel at clinical research sites depend on in order to run trials, allowing them to reduce their workload and “accelerate” clinical trial enrolment.

Reify Health CEO and co-founder Ralph Passarella said: “The life science industry spends over four billion dollars every year on technologies aimed at making clinical trials more efficient.

“Yet, very little of that investment goes towards technology that helps the frontline healthcare staff who enrol and care for patients.

“If we want to make clinical trials faster, cheaper, and more predictable, the industry can’t keep building technology that increases efficiency for some but decreases efficiency for those working directly with patients. We decided that we needed to change that.”

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

StudyTeam orderly ‘eliminates’ redundant work across the clinical trial process and generates insights that are used to speed-up trial process.

Over 1,800 research sites in 26 countries are already using Reify’s StudyTeam platform. Global biopharma companies, such as Eli Lilly and Amgen, also use Reify’s product.

Battery Ventures general partner Neeraj Agrawal said: “We see tremendous opportunity for Reify Health to transform the life sciences industry and are thrilled to partner with them to bring life-saving drugs to patients faster.

“Healthcare staff have no shortage of tools being ‘pushed’ to them by trial sponsors and can be jaded about new software as a result. It is fascinating to see how much clinical research sites love using StudyTeam, so much so that they proactively reach out to sponsors to get them onboard.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU